MDNAF (Medicenna Therapeutics) Short Interest


MDNAF Medicenna Therapeutics Corp MDNAF
29 GF Score
Price $0.30
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MDNAF vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Medicenna Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicenna Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's Short Interest falls into.


MDNAF
29GF Score
Medicenna Therapeutics Corp MDNAF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics Business Description

Other Exchanges MDNA:Canada
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
29GF Score

Get the complete analysis for MDNAF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price